AUTH/2207/2/09 - Cephalon v ProStrakan

Promotion of Abstral

  • Case number
    AUTH/2207/2/09
  • Complaint received
    11 February 2009
  • Completed
    16 March 2009
  • Appeal hearing
    No appeal
  • Review
    May 2009
  • Applicable Code year
    2008
  • Breach Clause(s)
    3.2
  • Sanctions applied
    Undertaking received
  • Additional sanctions

Case Summary

Cephalon alleged that the claim 'Rapid relief of breakthrough cancer pain from 10 minutes', used by ProStrakan to promote Abstral (sublingual fentanyl citrate tablet), was inconsistent with the particulars listed in the summary of product characteristics (SPC) in breach of the Code.

The detailed response from ProStrakan is given below.

The Panel noted that Section 5.1 of the Abstral SPC (Pharmacodynamics properties) stated that '…Abstral has been shown to induce significantly superior relief of breakthrough pain compared with placebo from 15 minutes after administration onwards…'. Section 4.2 of the SPC (Posology and method of administration) stated that 'if adequate analgesia is not obtained within 15-30 minutes of administration of a simple sublingual tablet, a second 100 microgram sublingual tablet may be administered'.

The Panel noted that the claim for 'Rapid relief of breakthrough cancer pain from 10 minutes' was based upon efficacy data from a study. Nonetheless the ten minute claim was inconsistent with the Abstral SPC and the Panel thus ruled a breach of the Code.